HK1218079A1 - 亞硝酸鹽的藥物製劑及其用途 - Google Patents

亞硝酸鹽的藥物製劑及其用途 Download PDF

Info

Publication number
HK1218079A1
HK1218079A1 HK16106249.8A HK16106249A HK1218079A1 HK 1218079 A1 HK1218079 A1 HK 1218079A1 HK 16106249 A HK16106249 A HK 16106249A HK 1218079 A1 HK1218079 A1 HK 1218079A1
Authority
HK
Hong Kong
Prior art keywords
pain
subject
study
pharmaceutical composition
pharmaceutically acceptable
Prior art date
Application number
HK16106249.8A
Other languages
English (en)
Chinese (zh)
Inventor
Christopher Kevil
Kyle Chan
Amol SOIN
Original Assignee
Theravasc Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravasc Inc. filed Critical Theravasc Inc.
Publication of HK1218079A1 publication Critical patent/HK1218079A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK16106249.8A 2013-02-20 2014-02-20 亞硝酸鹽的藥物製劑及其用途 HK1218079A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361767017P 2013-02-20 2013-02-20
US61/767017 2013-02-20
PCT/US2014/017432 WO2014130691A2 (en) 2013-02-20 2014-02-20 Pharmaceutical formulations of nitrite and uses thereof

Publications (1)

Publication Number Publication Date
HK1218079A1 true HK1218079A1 (zh) 2017-02-03

Family

ID=51391970

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16106249.8A HK1218079A1 (zh) 2013-02-20 2014-02-20 亞硝酸鹽的藥物製劑及其用途

Country Status (12)

Country Link
US (2) US9561249B2 (enExample)
EP (1) EP2958573B1 (enExample)
JP (1) JP2016509030A (enExample)
KR (1) KR102472588B1 (enExample)
CN (1) CN105358160A (enExample)
AU (1) AU2014218916A1 (enExample)
BR (1) BR112015019802A2 (enExample)
CA (1) CA2899602C (enExample)
DK (1) DK2958573T3 (enExample)
ES (1) ES2741146T3 (enExample)
HK (1) HK1218079A1 (enExample)
WO (1) WO2014130691A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9649334B2 (en) * 2007-11-15 2017-05-16 The Uab Research Foundation Use of nitrite salts in chronic ischemia
CN105358160A (zh) * 2013-02-20 2016-02-24 瑟阿瓦斯克公司 亚硝酸盐的药物制剂及其用途
GB201602959D0 (en) 2016-02-19 2016-04-06 Isis Innovation Use of cerebral nitric oxide donors in the assessment of the extent of brain dyfunction following injury
EP3463296A4 (en) * 2016-06-06 2020-02-19 Board of Supervisors of Louisiana State University and Agricultural and Mechanical College Pharmaceutical formulations of nitrite uses thereof
JP7179299B2 (ja) * 2017-07-14 2022-11-29 国立大学法人大阪大学 スパースモデリングを利用した痛みの分類および瞬間痛の判別
CN108785106B (zh) * 2018-06-05 2021-03-16 中国科学院上海硅酸盐研究所 一种胶状含银磷酸钙纳米复合材料及其制备方法和应用
CA3123524C (en) 2019-01-02 2024-01-23 Celagenex Research (India) Pvt. Ltd. Synergistic nutritional compositions for pain management
CN115335071A (zh) * 2019-10-28 2022-11-11 阿卡迪亚医药公司 用于治疗雷特综合征的方法和组合物

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650484A (en) 1983-02-03 1987-03-17 Alza Corporation Method for treating ischemic conditions
IE64726B1 (en) 1987-11-20 1995-08-23 Elan Corp Plc Pharmaceutical formulations for preventing drug tolerance
US5122384A (en) 1989-05-05 1992-06-16 Kv Pharmaceutical Company Oral once-per-day organic nitrate formulation which does not induce tolerance
US5278192A (en) 1992-07-02 1994-01-11 The Research Foundation Of State University Of New York Method of vasodilator therapy for treating a patient with a condition
US6709681B2 (en) 1995-02-17 2004-03-23 Aberdeen University Acidified nitrite as an antimicrobial agent
US20110196039A9 (en) 1994-10-05 2011-08-11 Kaesemeyer Wayne H Controlled release arginine formulations
US5648101A (en) * 1994-11-14 1997-07-15 Tawashi; Rashad Drug delivery of nitric oxide
US5692500A (en) * 1995-01-09 1997-12-02 Gaston-Johansson; Fannie Pain measurement and recording tool and method
US5770645A (en) 1996-08-02 1998-06-23 Duke University Medical Center Polymers for delivering nitric oxide in vivo
US5994444A (en) 1997-10-16 1999-11-30 Medtronic, Inc. Polymeric material that releases nitric oxide
US7371415B1 (en) 1998-04-03 2008-05-13 The Daily Wellness Company Method and composition for improving sexual fitness
US7015876B1 (en) 1998-06-03 2006-03-21 Lear Corporation Heads-up display with improved contrast
WO2000003725A1 (en) 1998-07-14 2000-01-27 Paracelsian, Inc. Method for identifying and confirming consistent bio-functionality of natural compositions
DE59905248D1 (de) 1999-01-29 2003-05-28 Disphar Int Bv Pharmazeutische zusammensetzungen
GB9905425D0 (en) 1999-03-09 1999-05-05 Queen Mary & Westfield College Pharmaceutical composition
GB0119011D0 (en) 2001-08-03 2001-09-26 Univ Aberdeen Treatment of nail infections
EP1336602A1 (en) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
EP1495026A4 (en) * 2002-03-20 2008-07-09 Univ Queensland METHOD AND COMPOSITIONS CONTAINING STAIN OXIDE DISPENSERS AND OPIOLD ANALGETICS
CA2379211A1 (fr) 2002-03-28 2003-09-28 Institut De Cardiologie De Montreal Utilisation du bleu de methylene pour renverser la reaction hemodynamique exageree induite par la combinaison d'un derive nitre et du sildenafil ou d'une molecule de meme classe (inhibiteur de la phosphodiesterase)
EP1653978B1 (en) 2003-07-09 2020-06-03 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Use of nitrite salts for the treatment of cardiovascular conditions
CA2536173A1 (en) 2003-08-20 2005-03-03 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
WO2005023189A2 (en) * 2003-09-03 2005-03-17 Pharmacia Corporation Method of cox-2 selective inhibitor and nitric oxide-donating agent
US7362274B1 (en) 2004-07-09 2008-04-22 Huan-Cheng Lien Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna
US20060083824A1 (en) 2004-10-20 2006-04-20 Pbm Products Llc Nutritional supplements for glucose intolerant individuals
WO2006128032A2 (en) 2005-05-24 2006-11-30 Wellgen, Inc. Compositions and methods for the prevention and treatment of conditions associated with inflammation
GB0607402D0 (en) 2006-04-12 2006-05-24 Barts & London Nhs Trust Therapeutic composition and use
US8333997B2 (en) 2006-06-21 2012-12-18 Albert Einstein College Of Medicine Of Yeshiva University Compositions for sustained release of nitric oxide, methods of preparing same and uses thereof
US9180140B2 (en) 2007-02-26 2015-11-10 Heartbeet Ltd. Performance enhancing composition and use thereof
AU2008219834C1 (en) 2007-02-26 2015-11-12 Heartbeet Ltd. New use of nitrites and nitrates and compositions containing these
WO2008153762A2 (en) 2007-05-25 2008-12-18 N30 Pharmaceuticals, Llc S-nitrosothiol formulations and storage systems
US9649334B2 (en) 2007-11-15 2017-05-16 The Uab Research Foundation Use of nitrite salts in chronic ischemia
AU2008345034A1 (en) 2007-12-27 2009-07-09 Aires Pharmaceuticals, Inc. Aerosolized nitrite and nitric oxide - donating compounds and uses thereof
WO2010036236A1 (en) 2008-09-23 2010-04-01 Baker Hughes Incorporated Anchor assembly
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
US20120237617A1 (en) * 2009-06-18 2012-09-20 Theravasc Inc. Use of nitrite salts in treating tissue damage
US20130209584A1 (en) 2009-10-14 2013-08-15 Theravasc Inc. Pharmaceutical formulations of nitrite and uses thereof
CA2777066C (en) * 2009-10-14 2020-02-18 TheraVasc, LLC Pharmaceutical formulations of nitrite and uses thereof
ES2553745T3 (es) * 2010-10-21 2015-12-11 Kipax Ab Dispositivo de suministro tópico dérmico para suministro de óxido nítrico
US20140127329A1 (en) 2011-03-31 2014-05-08 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Use of nitrites for the treatment of cerebral amyloid angiopathy, age associated dementia, and cognitive decline
WO2012142413A2 (en) 2011-04-14 2012-10-18 Theravasc Inc. Nitrite compositions and uses thereof
CN105358160A (zh) * 2013-02-20 2016-02-24 瑟阿瓦斯克公司 亚硝酸盐的药物制剂及其用途

Also Published As

Publication number Publication date
JP2016509030A (ja) 2016-03-24
CA2899602A1 (en) 2014-08-28
EP2958573B1 (en) 2019-05-08
US20150196588A1 (en) 2015-07-16
KR20150120479A (ko) 2015-10-27
US9561249B2 (en) 2017-02-07
EP2958573A4 (en) 2016-10-19
AU2014218916A1 (en) 2015-09-03
ES2741146T3 (es) 2020-02-10
WO2014130691A2 (en) 2014-08-28
EP2958573A2 (en) 2015-12-30
WO2014130691A3 (en) 2014-10-16
DK2958573T3 (da) 2019-08-05
BR112015019802A2 (pt) 2017-07-18
KR102472588B1 (ko) 2022-12-01
CA2899602C (en) 2024-01-30
US20170143759A1 (en) 2017-05-25
CN105358160A (zh) 2016-02-24

Similar Documents

Publication Publication Date Title
US9561249B2 (en) Pharmaceutical formulations of nitrite and uses thereof
US20220152054A1 (en) Methods and compositions for treating various disorders
JP6137833B2 (ja) 脱髄性および他の神経系疾患を患っている患者における神経認知的および/または神経精神医学的障害を改善するための4−アミノピリジンの使用
JP7539898B2 (ja) オピオイド鎮痛耐性を治療するためのmGluR5アンタゴニストの使用
WO2024102802A1 (en) Zelatriazin for the treatment of depression
CA2840521C (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation
Akgun et al. Central nervous system stimulants and drugs that suppress appetite
HK40081935A (en) Treatment of amyotrophic lateral sclerosis
US20130267533A1 (en) 5ht1a agonists for treatment of high cholesterol
WO2024054412A1 (en) Methods and compositions for treating amyotrophic lateral sclerosis